PI3K/Akt/mTOR · target hub
Protein kinase C iota type (PRKCI)
PRKCI is a PDK1–Akt axis or canonical effector on the PI3K/Akt/mTOR axis. Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in… It is indexed under "AGC kinases parallel / intersecting Akt–mTOR" on our pathway page for antibodies, inhibitors, and assay guidance.
| Type / example | Domain / context (brief) |
|---|---|
| Expression context | Tissue/cell-type–dependent expression |
| Rare variants | Sporadic variants—require functional validation |
| Pathway coupling | Co-occurs with neighboring nodes on the hub |
Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.
Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.
Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.
Overexpression vs endogenous PRKCI can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.
Adds PRKCI keyword bias atop the PI3K/Akt/mTOR antibody pool—if sparse, use presets above or global search.
This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.
Last reviewed: 2026-05-18
See the PI3K/Akt/mTOR hub for neighboring nodes and assay guidance—cross-check MAPK, RTK, metabolism, and autophagy pages as needed.